Your Cardiovascular Patients May Be At A Higher Risk Than You Know! Framingham Risk Scores alone are not enough.

Did You Know? :

Patients assessed as low risk with Framingham Risk Scores but who also had Endothelia Dysfunction, suffered 300% more adverse cardiac events over a 7 year period than those with low risk but normal endothelia function.

New Findings: New cardiovascular risk determinants.

Call Us Now: (281)364-8822

Endothelia Dysfunction

Give your practice, and your patients, a 21st Century Advantage.

Quick Links: Itamar Medical distributor

The EndoPAT™A New Standard for Endothelial Function Assessment

  • Endothelia function assessment can now be done in your office in 15 minutes by your medical assistant.
  • Tests are reimbursable by Medicare and commercial insurers.
  • Endothelia Dysfunction is treatable and reversible.
  • Endothelia Dysfunction is the risk of the risk factors.
EndoPAT Brochure PDF

EndoPAT™ is the leading medical device for noninvasive endothelial function assessment. It is FDA-cleared, CE-marked and used in preeminent clinical institutions, research centers and Pharmaceutical clinical phase studies in over 40 countries.

Some of the features that make Endo-PAT appealing are its ease of use, user-independence and immediate, automatically calculated test results. It provides clinicians with a reliable and reproducible index of endothelial function in a 15-minute, office-based test.

It is incorporated into numerous multi-center and population-based studies such as the Framingham Heart Study. Research using Endo-PAT has yielded more than 100 articles in peer-reviewed journals and abstracts. It is becoming widely recognized as the standard method for endothelial function assessment.

Scroll To Top